Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

Chandler Macleod: Yield And Growth

Jul 05 2012

Human Resources and employment services group Chandler Macleod offers strong earnings growth and an attractive yield, which sees Moelis rate the stock a Buy.


Skilled Group Offers Value

Jul 03 2012

Credit Suisse has initiated coverage on Skilled Group with an Outperform rating, citing earnings and dividend growth potential.


Hi Ho Silver For Alcyone

Jun 28 2012

DJ Carmichael has initiated coverage on Alcyone Resources with a Spec Buy, attracted to the emerging silver producer for its leverage to silver prices and exploration upside.


UXC Offering Attractive IT Exposure, With Yield

Jun 27 2012

Moelis explains why UXC is its sole Buy rating in the Australian IT sector.


Breville Quietly Conquering America

Jun 21 2012

Breville Group continues to deliver growth from its international operations and this sees Moelis reiterate a Buy rating on the stock.


Central Petroleum Has Re-Rating Potential

Jun 19 2012

Central Petroeum has one of the world’s largest onshore oil and gas acreage positions and given the potential for a re-rating DJ Carmichael initiatives coverage with a Spec Buy rating.


NIB Holdings: (Special) Dividends With Upside

Jun 18 2012

Macquarie has initiated coverage on private health insurer NIB Holdings pointing at an attractive valuation and a focus on capital returns.


SFG Australia Offers Upside Plus Yield

Jun 12 2012

SFG Australia shares offer upside from ongoing growth in funds under management plus an attractive dividend yield, reports stockbroker Moelis.


Modest Growth Supports Programmed’s Value Proposition

May 31 2012

Programmed Maintenance Services beat consensus with its full year results and modest growth expectations for FY13 see all brokers in the FNArena database rate the stock a Buy.


Neuren Story Getting Better

May 25 2012

Neuren Pharmaceuticals is making progress with its traumatic brain injury drug and Bell Potter reiterates a Buy rating.



Analyse The Market From A Different Angle